0 10 Regulation regulation NN 11 13 of of IN 14 21 nuclear nuclear JJ 22 34 factor-kappa factor-kappa NN 35 36 B B NNP 37 40 and and CC 41 44 its its PRP$ 45 54 inhibitor inhibitor NN 55 56 I i NN 57 62 kappa kappa NN 63 76 B-alpha/MAD-3 b-alpha/mad-3 NN 77 79 in in IN 80 89 monocytes monocyte NNS 90 92 by by IN 93 106 Mycobacterium Mycobacterium NNP 107 119 tuberculosis tuberculosis NN 120 123 and and CC 124 130 during during IN 131 136 human human JJ 137 149 tuberculosis tuberculosis NN 149 150 . . . 152 157 Blood Blood NNP 158 167 monocytes monocyte NNS 168 172 from from IN 173 181 patients patient NNS 182 186 with with IN 187 193 active active JJ 194 206 tuberculosis tuberculosis NN 207 210 are be VBP 211 220 activated activate VBN 221 223 in in FW 224 228 vivo vivo FW 228 229 , , , 230 232 as as IN 233 242 evidenced evidence VBN 243 245 by by IN 246 248 an an DT 249 257 increase increase NN 258 260 in in IN 261 264 the the DT 265 275 stimulated stimulate VBN 276 283 release release NN 284 286 of of IN 287 302 proinflammatory proinflammatory JJ 303 312 cytokines cytokine NNS 312 313 , , , 314 318 such such JJ 319 321 as as IN 322 331 TNF-alpha TNF-alpha NNP 331 332 , , , 333 336 and and CC 337 340 the the DT 341 352 spontaneous spontaneous JJ 353 363 expression expression NN 364 366 of of IN 367 373 IL-2R. IL-2R. NNP 374 381 Further further RB 381 382 , , , 383 392 monocytes monocyte NNS 393 397 from from IN 398 406 patients patient NNS 407 418 demonstrate demonstrate VBP 419 421 an an DT 422 431 augmented augmented JJ 432 446 susceptibility susceptibility NN 447 449 to to TO 450 451 a a DT 452 462 productive productive JJ 463 472 infection infection NN 473 477 with with IN 478 483 HIV-1 HIV-1 NNP 484 486 in in FW 487 492 vitro vitro FW 492 493 . . . 494 507 Mycobacterium Mycobacterium NNP 508 520 tuberculosis tuberculosis NN 521 524 and and CC 525 528 its its PRP$ 529 539 components component NNS 540 543 are be VBP 544 550 strong strong JJ 551 558 signals signal NNS 559 561 to to TO 562 570 activate activate VB 571 580 monocytes monocyte NNS 581 583 to to TO 584 594 production production NN 595 597 of of IN 598 607 cytokines cytokine NNS 607 608 . . . 609 611 In in IN 612 616 this this DT 617 622 study study NN 623 625 we we PRP 626 634 examined examine VBD 635 638 the the DT 639 644 basis basis NN 645 647 of of IN 648 658 activation activation NN 659 661 of of IN 662 671 monocytes monocyte NNS 672 678 during during IN 679 685 active active JJ 686 698 tuberculosis tuberculosis NN 699 702 and and CC 703 705 by by IN 706 708 M. M. NNP 709 721 tuberculosis tuberculosis NN 721 722 . . . 723 725 We we PRP 726 731 found find VBD 732 733 a a DT 734 746 constitutive constitutive JJ 747 758 degradation degradation NN 759 761 of of IN 762 763 I i NN 764 769 kappa kappa NN 770 777 B-alpha B-alpha NNP 777 778 , , , 779 782 the the DT 783 788 major major JJ 789 800 cytoplasmic cytoplasmic JJ 801 810 inhibitor inhibitor NN 811 813 of of IN 814 821 nuclear nuclear JJ 822 828 factor factor NN 829 834 kappa kappa NN 835 836 B B NNP 837 838 ( ( ( 838 846 NF-kappa NF-kappa NNP 847 848 B B NNP 848 849 ) ) ) 849 850 , , , 851 853 in in IN 854 861 freshly freshly RB 862 870 isolated isolate VBN 871 875 PBMC PBMC NNP 876 879 and and CC 880 889 monocytes monocyte NNS 890 894 from from IN 895 903 patients patient NNS 904 908 with with IN 909 921 tuberculosis tuberculosis NN 921 922 . . . 923 925 In in IN 926 934 contrast contrast NN 934 935 , , , 936 937 I i NN 938 943 kappa kappa NN 944 951 B-alpha B-alpha NNP 952 958 levels level NNS 959 961 in in IN 962 966 PBMC PBMC NNP 967 970 and and CC 971 980 monocytes monocyte NNS 981 985 from from IN 986 993 healthy healthy JJ 994 1002 subjects subject NNS 1003 1005 or or CC 1006 1010 from from IN 1011 1019 patients patient NNS 1020 1024 with with IN 1025 1039 nontuberculous nontuberculous JJ 1040 1049 pulmonary pulmonary JJ 1050 1060 conditions condition NNS 1061 1065 were be VBD 1066 1072 intact intact JJ 1072 1073 . . . 1074 1081 Further further RB 1081 1082 , , , 1083 1085 by by IN 1086 1101 electrophoretic electrophoretic JJ 1102 1110 mobility mobility NN 1111 1116 shift shift NN 1117 1122 assay assay NN 1122 1123 , , , 1124 1132 NF-kappa NF-kappa NNP 1133 1134 B B NNP 1135 1138 was be VBD 1139 1148 activated activate VBN 1149 1151 in in IN 1152 1161 monocytes monocyte NNS 1162 1166 from from IN 1167 1178 tuberculous tuberculous JJ 1179 1187 patients patient NNS 1187 1188 . . . 1189 1192 The the DT 1193 1203 expression expression NN 1204 1206 of of IN 1207 1208 I i NN 1209 1214 kappa kappa NN 1215 1222 B-alpha B-alpha NNP 1223 1227 gene gene NN 1227 1228 , , , 1229 1234 which which WDT 1235 1237 is be VBZ 1238 1248 responsive responsive JJ 1249 1251 to to TO 1252 1262 activation activation NN 1263 1265 by by IN 1266 1274 NF-kappa NF-kappa NNP 1275 1276 B B NNP 1276 1277 , , , 1278 1281 was be VBD 1282 1294 up-regulated up-regulate VBN 1295 1297 in in IN 1298 1302 PBMC PBMC NNP 1303 1306 and and CC 1307 1316 monocytes monocyte NNS 1317 1321 from from IN 1322 1330 patients patient NNS 1330 1331 , , , 1332 1335 but but CC 1336 1339 not not RB 1340 1342 in in IN 1343 1354 mononuclear mononuclear JJ 1355 1360 cells cell NNS 1361 1365 from from IN 1366 1373 healthy healthy JJ 1374 1382 subjects subject NNS 1383 1385 or or CC 1386 1391 those those DT 1392 1396 with with IN 1397 1411 nontuberculous nontuberculous JJ 1412 1416 lung lung NN 1417 1425 diseases disease NNS 1425 1426 . . . 1427 1429 By by IN 1430 1438 contrast contrast NN 1438 1439 , , , 1440 1443 the the DT 1444 1454 expression expression NN 1455 1457 of of IN 1458 1463 other other JJ 1464 1484 adherence-associated adherence-associated JJ 1485 1490 early early JJ 1491 1496 genes gene NNS 1496 1497 , , , 1498 1502 such such JJ 1503 1505 as as IN 1506 1510 IL-8 il-8 NN 1511 1514 and and CC 1515 1519 IL-1 il-1 NN 1520 1524 beta beta NN 1524 1525 , , , 1526 1529 was be VBD 1530 1533 not not RB 1534 1546 up-regulated up-regulate VBN 1547 1549 in in IN 1550 1554 PBMC PBMC NNP 1555 1557 of of IN 1558 1569 tuberculous tuberculous JJ 1570 1578 patients patient NNS 1578 1579 . . . 1580 1587 Further further RB 1587 1588 , , , 1589 1591 M. M. NNP 1592 1604 tuberculosis tuberculosis NN 1605 1608 and and CC 1609 1612 its its PRP$ 1613 1623 tuberculin tuberculin NN 1623 1624 , , , 1625 1633 purified purify VBN 1634 1641 protein protein NN 1642 1652 derivative derivative NN 1652 1653 , , , 1654 1661 induced induce VBD 1662 1665 the the DT 1666 1677 degradation degradation NN 1678 1680 of of IN 1681 1682 I i NN 1683 1688 kappa kappa NN 1689 1696 B-alpha B-alpha NNP 1697 1700 and and CC 1701 1704 the the DT 1705 1715 expression expression NN 1716 1718 of of IN 1719 1720 I i NN 1721 1726 kappa kappa NN 1727 1734 B-alpha B-alpha NNP 1735 1739 mRNA mRNA NNP 1739 1740 , , , 1741 1744 and and CC 1745 1753 purified purify VBN 1754 1761 protein protein NN 1762 1772 derivative derivative NN 1773 1780 induced induce VBD 1781 1784 the the DT 1785 1795 activation activation NN 1796 1798 of of IN 1799 1807 NF-kappa NF-kappa NNP 1808 1809 B B NNP 1810 1812 in in IN 1813 1822 monocytes monocyte NNS 1822 1823 . . .